Diabetes and the kidney

Authors: Tahseen A Chowdhury and Omer Ali

Diabetes is the most common cause of end-stage kidney disease. Randomised controlled trials have shown a significant benefit of sodium-glucose transporter-2 inhibitors in patients with diabetic kidney disease (DKD), and guidelines now suggest these drugs should be considered in all patients with DKD irrespective of glucose control. Glucagon-like peptide-1 receptor agonists have shown some benefit in reducing progression of albuminuria in DKD and should also be considered early in the therapeutic pathway. Management of diabetes in patients on renal replacement therapy (dialysis or transplantation) is uniquely challenging. This article outlines guidance on management of glucose in these vulnerable groups of patients.

Introduction
Diabetes prevalence worldwide, particularly that of type 2 diabetes (T2D) is rapidly increasing. Diabetes is the most common cause of end-stage renal disease (ESRD) worldwide; it is estimated that around 40% of people living with T2D have diabetic kidney disease (DKD). The presence of chronic kidney disease (CKD) or albuminuria are independent predictors of cardiovascular morbidity and mortality in people with diabetes.

Here, we review developments in the management of patients with T2D and DKD over recent years. In addition, we discuss the management of hyperglycaemia in patients with diabetes on renal replacement therapy (RRT; dialysis or renal transplantation).

Management of diabetic nephropathy: a new paradigm
Diagnosis of DKD
DKD is a clinical diagnosis defined as persistently reduced estimated glomerular filtration rate (eGFR) (<60 mL/min/1.73 m²) and/or the presence of microalbuminuria (albumin/creatinine ratio (ACR) 3–30 mg/mmol) / macroalbuminuria (ACR >30 mg/mmol) among patients with diabetes. Every person living with diabetes (type 1 diabetes (T1D), T2D and other forms) should undergo at least annual tests of eGFR and ACR, ideally using a first voided urine sample. Elevated ACR should be confirmed with a repeat sample, as recent exercise or a high protein meal may elevate ACR in the absence of significant renal disease.

The finding of an elevated ACR in a person with diabetes should elicit further investigation. Not all renal disease in people with diabetes is DKD; therefore, dipstick testing for haematuria and exclusion of urinary tract infection (UTI) is a minimum requirement. Presence of haematuria requires further investigation. Other clues to the possibility of non-diabetes-related kidney disease include the absence of diabetic retinopathy, severe or resistant hypertension, previously normal ACR, rapid worsening of eGFR or the presence of systemic illness. In the absence of these findings, most people with diabetes and elevated ACR will have DKD, and require no further investigation.

Management of DKD
Management of DKD involves tight control of blood pressure (<130/80 mmHg) using angiotensin converting enzyme inhibitors.

Key points
- Diabetic kidney disease is an important cause of end-stage renal disease, and early detection and management may prevent or delay development of renal failure.
- Prescription of sodium-glucose transporter-2 inhibitor drugs to people with type 2 diabetes who have evidence of chronic kidney disease or albuminuria should be considered, irrespective of glucose control, and in addition to renin-angiotensin system blockade therapy.
- Glucagon-like peptide-1 receptor analogues are also useful in diabetic kidney disease and should be considered early in the therapeutic pathway.
- For patients with diabetes on haemodialysis, avoidance of hypoglycaemia is paramount. Use of continuous or flash glucose monitoring systems may facilitate adjustment of glucose lowering therapy.
- Post-transplant diabetes mellitus is an important clinical entity, and requires active screening and management.

Keywords: diabetes, nephropathy, sodium-glucose transporter-2, dialysis, transplantation

DOI: 10.7861/clinmed.2021-0144
(ACEI) or angiotensin receptor blockers (ARB) as a first-line therapy. Even in the absence of hypertension, ACEI or ARB therapy should be offered, to maximum tolerated dose, with advice for avoidance of pregnancy in women of child bearing age. Patients with DKD are frequently multi-morbid, often living with a number of long-term conditions and frailty. Attempts to optimise glycaemic control should be undertaken, taking care to avoid hypoglycaemia in older or multi-morbid patients. Cardiovascular risk reduction with statins, lifestyle advice and smoking cessation should be strongly advocated, as well as regular screening for diabetes complications. eGFR should be measured at least 6 monthly.

Nephrological advice should be sought in patients with rapidly deteriorating renal function, rising ACR despite optimal treatment or eGFR <30 mL/min/1.73 m² when discussions about RRT will need to be undertaken.

New treatments for DKD

Over the past 2 decades, a number of interventions to limit the deterioration of renal function in DKD have shown promise, but have shown little benefit in randomised controlled trials (RCTs). These interventions include combined ACEI/ARB therapy, use of direct renin inhibitors, bardoxolone and endothelin-A receptor antagonists. In the last 5 years, however, cardiovascular outcomes trials (CVOTs) of newer agents used in T2D have led to important renal outcome data which now inform clinical practice.

**Sodium-glucose transporter-2 inhibitors**

Sodium-glucose transporter-2 inhibitors (SGLT-2i) act on the proximal renal tubule to induce glycosuria. They have a modest effect on improving glucose control, with a reduction of glycated haemoglobin (HbA₁c) −10 mmol/mol (1%). They can improve body weight and blood pressure. Common adverse effects include genital mycotic infections or UTI. Less commonly, SGLT-2i may cause euglycaemic ketoacidosis, characterised by relative normoglycaemia and presence of ketoacidosis in a person with normoglycaemia and presence of ketoacidosis in a person with T2D. Careful patient education around sick day rules is needed (Box 1), including avoidance prior to surgery and avoidance of ketogenic diets.

Several large RCTs suggest significant benefit of SGLT-2i drugs in patients with DKD independent of their effect on glycaemia. Most compelling of these studies was CREDENCE, which examined renal outcomes in patients treated with canagliflozin or placebo in 4,401 patients with T2D, CKD (mean eGFR 56.2 mL/min/1.73 m²) and albuminuria. Canagliflozin treatment was associated with a 34% reduction in the renal specific composite of doubling of baseline creatinine, ESRD or death from renal or cardiovascular causes (hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.53−0.81; p<0.001). Canagliflozin also reduced three-point major adverse cardiovascular outcomes (3p-MACE) by 20% (HR 0.80; 95% CI 1.07−0.95; p<0.01) and hospitalisation for heart failure (hHF) by 39% (HR 0.61; 95% CI 0.47−0.90; p<0.001). The numbers needed to treat (NNT) to prevent one renal outcome was 21.

Meta-analysis confirms favourable effects of SGLT-2i on the renal composite of doubling of serum creatinine (eGFR 40% decline), RRT initiation or renal death (risk reduction (RR) 0.63; 95% CI 0.56−0.71). Pooled NNT for renal outcomes was 67. The effects appear to be strongest among those patients with albuminuria, and the effect is additive to ACEI or ARB use.

**Glucagon-like peptide-1 receptor agonists**

Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a potent glucose lowering effect by mimicking the effect of incretin hormones in stimulating insulin release, reducing glucagon and reducing appetite. They aid significant weight reduction. Adverse effects are predominantly gastrointestinal disturbance and, more rarely, pancreatitis. GLP-1RAs have shown promising results in CVOTs. Meta-analysis of 56,004 patients showed a 12% reduction of risk for hospitalisation for heart failure (hHF) by 39% (HR 0.61; 95% CI 0.47−0.90; p<0.001).

**Box 1. Sick day rules when a person with diabetes is not well**

When a person with diabetes is not well or is unable to eat and drink as normal, some simple rules can help prevent further deterioration or development of diabetic ketoacidosis.

- Measure capillary ketones: using self-testing equipment or at hospital.
- If >1.5 mmol/L, then attend the local emergency department immediately for testing for possible diabetic ketoacidosis.
- Take half glass of milk, fruit juice, yogurt or soups (not clear soups), if not able to eat and if taking insulin, cover with half the normal dose of insulin.
- Drink plenty of water / sugar free fluid to avoid dehydration for up to 24 hours.
- Seek medical advice if infection or illness worsens.
- Be aware that glucose levels can be normal because of the way sodium-glucose transporter-2 inhibitors work. Ketone levels can be high, even with a normal glucose.
- Some medications are not good when you are not well. Diabetes Medicine to Stop Temporarily when not well (DAMN GlucoSe drugs; discuss with your doctor):
  - diuretics: ‘water pills’ eg frusemide, bendroflumethiazide, indapamide or bumetanide
  - angiotensin converting enzyme inhibitors: names ending in ‘pril’ eg ramipril, lisinopril or perindopril
  - angiotensin receptor blockers: names ending in ‘sartan’ eg candesartan, losartan or irbesartan
  - metformin
  - non-steroidal anti-inflammatory drugs: anti-inflammatory pain killers eg ibuprofen, naproxen or diclofenac
  - glucagon-like peptide-1 analogues (injectable): names ending in ‘tide’ eg exenetide, liraglutide, dulaglutide or semaglutide
  - sodium-glucose transporter-2 inhibitors: names ending in ‘floxin’ eg canagliflozin, dapagliflozin, empagliflozin or ertugliflozin.

Based on this evidence, canagliflozin is now considered an effective option for renal and cardiovascular protection in DKD, and can be initiated in patients with T2D and macroalbuminuria, and eGFR >30 mL/min/1.73 m² as add-on to ACEI, irrespective of glucose control. It can be continued below eGFR 30 mL/min/1.73 m². It is expected that dapagliflozin will obtain a similar licence in due course as it has equally compelling data more recently published.

In contrast to ACEI/ARBs, renoprotective effects of SGLT-2i are thought to be mediated by tubuloglomerular feedback, natriuresis and glucose induced osmotic diuresis which reduces intraglomerular pressure.
in 3p-MACE in GLP-1RA treated patients. \(^1\) A composite renal outcome was reduced by 17% for all GLP1-RA, but this is mainly due to a reduction in new onset macroalbuminuria, rather than a reduction in progressive renal disease, ESRD or renal-related death. Liraglutide, dulaglutide and semaglutide have demonstrated effective glycaemic control in T2D and CKD and are licensed for use down to eGFR 15 mL/min/1.73 m\(^2\).

**Aldosterone receptor antagonist**
A study of the aldosterone receptor antagonist, Finerenone in 5,734 patients with T2D and CKD showed some positive outcomes. \(^1\) ESRD, sustained decrease of >60% in eGFR or death from renal causes was reduced by 18% in the Finerenone group (HR 0.82; 95% CI 0.73–0.93; p = 0.001). Hyperkalaemia due to Finerenone occurred in 2.3% of patients treated.

Recent guidelines on management of DKD
Current UK guidance based on the National Institute for Health and Care Excellence (NICE) has not been updated since 2015. More recently, updated UK guidelines from the Association of British Clinical Diabetologists (ABCD) and The Renal Association (RA) advocate SGLT-2i in all patients with T2D and CKD or albuminuria irrespective of glucose control. \(^1\) Furthermore, guidance from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) recommend that SGLT-2i should be used in any patient with T2D with heart failure or CKD. \(^1\)

**Diabetes on dialysis**
Diabetes is common among patients on haemodialysis (HD) and managing glucose control in people with diabetes on HD can be challenging. Dialysis improves uraemia, acidosis and hyperphosphataemia which can periodically improve insulin secretion, leading to risk of hypoglycaemia, and symptoms of hypoglycaemia may be confused with hypotension. Furthermore, assessment of glucose control may be tricky due to difficulties in interpretation of HbA\(_1c\), in renal anaemia. Glycaemic management is therefore reliant on frequent self-monitoring of blood glucose (SMBG) which is burdensome. In addition, a number of anti-hyperglycaemic agents (such as metformin, SGLT-2i and GLP-1RA) cannot be used in dialysis patients, further adding to the challenge.

Guidance on the management of diabetes in patients on HD has been published and is due to be updated. \(^1\) There is some evidence that asymptomatic hypoglycaemia is common among patients on HD, and therefore updated guidance is likely to suggest that use of continuous or flash glucose monitoring (CGM or FGM) technology may help in the management of patients with diabetes on HD (Fig 1). Intermittent ‘diagnostic’ use of CGM or FGM in patients on insulin or sulphonylurea on HD. NHS guidance on the use of the FGM (Freestyle Libre) includes any form of diabetes on HD on insulin.

Management of glycaemia in patients on peritoneal dialysis can be even more challenging especially when high glucose dialysate fluids are used. This can lead to a vicious cycle of hyperglycaemia, increased fluid intake and fluid overload, necessitating higher dialysate concentrations. CGM or FGM may be useful to gain a clear understanding of glucose variability with dialysate bags to enable adjustment of insulin doses on dialysis and non-dialysis days.

**Post-transplant diabetes mellitus**
Advances in immunosuppression have enabled dramatic improvements in outcomes of solid organ transplantation (SOT), with major improvements in graft and patient survival. Morbidity and mortality from cardiovascular disease is, however, increasing, and diabetes is a major contributor. Diabetes may pre-date transplantation, but is also a common consequence of transplantation, affecting between 10%–40% of SOT recipients. Post-transplant diabetes mellitus (PTDM) confers a significantly higher risk of graft failure and mortality. \(^1\) Guidance on the diagnosis, management and prevention of PTDM have been developed by the ABCD and RA. \(^2\)

**Pathogenesis**
Weight gain (due to glucocorticoids and fewer dietary restrictions) is common in patients post-SOT. While excess weight, ethnicity and sedentary lifestyles are all risk factors for development of PTDM, other risk factors include immunosuppression (especially calcineurin inhibitors (CNIs)) and infection (eg hepatitis C). Tacrolimus is a highly effective immunosuppressant but has a potent adverse effect on beta-cell function, leading more frequently to significant hyperglycaemia compared with ciclosporin.

**Diagnosis**
Early hyperglycaemia is ubiquitous in SOT recipients due to stress, infection and immunosuppression. In the immediate post-transplant period, screening for post-transplant hyperglycaemia should involve frequent capillary blood glucose (CBG) testing, mainly later in the day (post-lunch or evening meal). A subsequent diagnosis of PTDM should only be confirmed by oral glucose tolerance test or HbA\(_1c\) at least 3 months post-transplant, when immunosuppression is stabilised.

**Management**
Early post-transplant hyperglycaemia requires active monitoring and management (Fig 1). Mild hyperglycaemia may respond to oral hypoglycaemic agents, but CBGs >14 mmol/L require intravenous or subcutaneous insulin. Subsequent management should mirror that of T2D pathways. Concern about the risk of urinary infection with SGLT-2i agents has limited their use in this condition, but their reno-protective effects may be very useful in PTDM, and small studies suggest no increase in risk of infection. Outcomes of larger studies are awaited. Change in immunosuppression regimen may aid management of hyperglycaemia and, if feasible, consideration may be given for conversion of tacrolimus to other immunosuppressive regimens in patients with difficult hyperglycaemia.

PTDM may be most effectively managed in a multidisciplinary setting with diabetes and transplant specialists.

**Conclusion**
Management of early DKD using SGLT-2i irrespective of glycaemic control is highly evidence based and recommended by a number of guidelines. This evidence needs to be implemented as it is likely to be highly cost effective to prevent progression to ESRD.
Patients with diabetes on RRT (dialysis or transplantation) may have particular challenges and require multidisciplinary management between diabetes and renal specialists. New guidelines are available to help manage these complex and vulnerable patients.

References


Address for correspondence: Dr Tahseen A Chowdhury, 7th Floor, John Harrison House, The Royal London Hospital, Whitechapel, London E1 1BB, UK.
Email: tahseen.chowdhury@nhs.net